UAE First to Approve New Hypertension Treatment Globally

Millions of people with high blood pressure struggle to control it even after trying multiple medications. Now, the UAE has opened a door to hope by becoming the first nation globally to approve Baxfendy, an innovative treatment that works differently than conventional options.

The Emirates Drug Establishment greenlit this new medication developed by AstraZeneca for patients whose blood pressure remains dangerously high despite taking other medicines. The drug contains baxdrostat, which targets a specific enzyme responsible for producing aldosterone, a hormone that raises blood pressure.

This approval matters because hypertension affects roughly one in three adults in the UAE, making it one of the country's most common chronic conditions. Many of these patients don't respond well to standard treatments, leaving them at risk for heart attacks, strokes, and other serious complications.

Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, emphasized the significance of bringing advanced solutions to patients faster. The approval reflects the UAE's commitment to flexible regulatory frameworks that prioritize getting life changing treatments to people who need them.

Two major clinical trials called BaxHTN and Bax24 showed that Baxfendy significantly reduced blood pressure when added to existing therapies. The results were both statistically significant and clinically meaningful, giving doctors confidence in prescribing it to patients who have run out of options.

The Ripple Effect

This approval sends waves beyond the UAE's borders. By being first to approve this treatment, the country sets an example for how regulatory agility can accelerate access to innovation while maintaining safety standards.

Other nations will now watch how the medication performs in real world settings. Success here could speed up approvals elsewhere, potentially helping millions of patients worldwide who struggle with resistant hypertension.

The move also strengthens the UAE's position as a hub for pharmaceutical innovation in the Middle East. It demonstrates that smaller nations can lead in healthcare advancement when they prioritize patient needs and streamline approval processes.

Sameh El Fangary from AstraZeneca expressed commitment to working with UAE partners to ensure patients can actually access this innovation. Approval is just the first step; getting the medication into pharmacies and making it affordable matters just as much.

This breakthrough represents more than just one new drug. It shows what's possible when regulators, pharmaceutical companies, and healthcare systems align around a common goal: giving patients better tools to manage chronic diseases and live healthier, longer lives.